{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:48:53Z","timestamp":1791942533760,"version":"4.3.4"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"abstract":"<jats:p>The treatment of hepatitis C virus (HCV) infection has progressed markedly over the last 2 decades, with a dramatic acceleration the last 3 years. The combination of two or three direct-acting antiviral drugs (DAAs) targeting viral proteins [NS3\/4A protease inhibitors, NS5B nucleos(t)idic and non-nucleos(t)idic polymerase inhibitors, NS5A replication complex inhibitors], with or without ribavirin but without interferon (interferon-free regimen), for 8\u201324 weeks, achieved high sustained virological response (&amp;gt;90%), whatever fibrosis stage, genotype and subtype, baseline viral load, prior therapeutic history of the patient (na\u00efve or experienced) and pre-existing resistance-associated variants with a fair tolerance and reduced pill burden. International guidelines recommend to ideally treat all infected patients even if a prioritization of the most severe patients (extensive fibrosis or cirrhosis, symptomatic cryoglobulinaemic vasculitis\u2026) appears to be the best cost-effective and urgent policy. Patients with stage 4\u20135 chronic kidney disease (CKD) have to be considered as priority patients. Updating of the Kidney Disease: Improving Global Outcomes recommendations is due to start soon, but awaiting their availability, we present here an overview of recent developments in the field.<\/jats:p>","DOI":"10.1093\/ndt\/gfw023","type":"journal-article","created":{"date-parts":[[2016,3,22]],"date-time":"2016-03-22T21:08:23Z","timestamp":1458680903000},"page":"32-35","source":"Crossref","is-referenced-by-count":4,"title":["An update on the management of hepatitis C virus-infected patients with stage 4\u20135 chronic kidney disease while awaiting the revised KDIGO Guidelines"],"prefix":"10.1093","volume":"32","author":[{"given":"Stanislas","family":"Pol","sequence":"first","affiliation":[{"name":"1Universit\u00e9 Paris Descartes, Paris, France"},{"name":"2Hepatology Department, Cochin Hospital, APHP, Paris, France"},{"name":"3INSERM UMS-20, Institut Pasteur, Paris, France and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Jadoul","sequence":"additional","affiliation":[{"name":"4Department of Nephrology, Cliniques universitaires Saint-Luc, Universit\u00e9 catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Vallet-Pichard","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 Paris Descartes, Paris, France"},{"name":"2Hepatology Department, Cochin Hospital, APHP, Paris, France"},{"name":"3INSERM UMS-20, Institut Pasteur, Paris, France and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,3,22]]},"reference":[{"key":"2025102312490093100_gfw023-B1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C infection","volume":"55","year":"2011","journal-title":"J Hepatol"},{"key":"2025102312490093100_gfw023-B2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1053\/j.ajkd.2014.04.005","article-title":"Hepatitis C treatment in dialysis patients: is a new dawn approaching?","volume":"64","author":"Gordon","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2025102312490093100_gfw023-B3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015.","volume":"63","author":"European Association for the Study of the Liver","year":"2015","journal-title":"J Hepatol"},{"key":"2025102312490093100_gfw023-B4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/j.ajkd.2012.04.003","article-title":"Association of hepatitis C virus infection with risk of ESRD: a population-based study","volume":"60","author":"Su","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2025102312490093100_gfw023-B5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study","volume":"206","author":"Lee","year":"2012","journal-title":"J Infect Dis"},{"key":"2025102312490093100_gfw023-B6","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.27664","article-title":"Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans","volume":"61","author":"Molnar","year":"2015","journal-title":"Hepatology"},{"key":"2025102312490093100_gfw023-B7","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/jvh.12413","article-title":"A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection","volume":"22","author":"Park","year":"2015","journal-title":"J Viral Hepat"},{"key":"2025102312490093100_gfw023-B8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","article-title":"Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection","volume":"64","author":"Hsu","year":"2015","journal-title":"Gut"},{"key":"2025102312490093100_gfw023-B9","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1111\/j.1523-1755.2004.00649.x","article-title":"Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS","volume":"65","author":"Fissell","year":"2004","journal-title":"Kidney Int"},{"key":"2025102312490093100_gfw023-B10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-150-1-200901060-00007","article-title":"Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998\u20132008","volume":"150","author":"Thompson","year":"2009","journal-title":"Ann Intern Med"},{"key":"2025102312490093100_gfw023-B11","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1093\/ndt\/gfq696","article-title":"Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey","volume":"26","author":"Saun\u00e9","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312490093100_gfw023-B12","first-page":"S1","article-title":"KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease","volume":"109","author":"Kidney Disease: Improving Global Outcomes","year":"2008","journal-title":"Kidney Int Suppl"},{"key":"2025102312490093100_gfw023-B13","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1097\/01.ASN.0000100127.54107.57","article-title":"Association of comorbid conditions and mortality in haemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"14","author":"Goodkin","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"2025102312490093100_gfw023-B14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2893.2012.01633.x","article-title":"Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?","volume":"19","author":"Fabrizi","year":"2012","journal-title":"J Viral Hepat"},{"key":"2025102312490093100_gfw023-B15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2893.2007.00868.x","article-title":"The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies","volume":"14","author":"Fabrizi","year":"2007","journal-title":"J Viral Hepat"},{"key":"2025102312490093100_gfw023-B16","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/j.1600-6143.2005.00864.x","article-title":"Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies","volume":"5","author":"Fabrizi","year":"2005","journal-title":"Am J Transplant"},{"key":"2025102312490093100_gfw023-B17","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/TP.0b013e3181f92548","article-title":"Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand","volume":"90","author":"Scott","year":"2010","journal-title":"Transplantation"},{"key":"2025102312490093100_gfw023-B18","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/00007890-199706150-00017","article-title":"Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients","volume":"63","author":"Morales","year":"1997","journal-title":"Transplantation"},{"key":"2025102312490093100_gfw023-B19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1034\/j.1600-6143.2001.10212.x","article-title":"Hepatitis C virus infection and de novo glomerular lesions in renal allografts","volume":"1","author":"Cruzado","year":"2001","journal-title":"Am J Transplant"},{"key":"2025102312490093100_gfw023-B20","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/TP.0b013e3181837761","article-title":"Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation","volume":"86","author":"Hoffmann","year":"2008","journal-title":"Transplantation"},{"issue":"(Suppl 3)","key":"2025102312490093100_gfw023-B21","first-page":"S52","article-title":"Clinical practice guideline for the care of kidney transplant recipients","volume":"9","author":"Kidney Disease: Improving Global Outcomes","year":"2009","journal-title":"Am J Transplant"},{"key":"2025102312490093100_gfw023-B22","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/ndt\/gfu047","article-title":"Impact of liver fibrosis staging in hepatitis C virus (HCV) patients with kidney failure","volume":"29","author":"Jadoul","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312490093100_gfw023-B23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jhep.2012.02.020","article-title":"Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection","volume":"57","author":"Cosconea","year":"2015","journal-title":"J Hepatol"},{"key":"2025102312490093100_gfw023-B24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000355615","article-title":"Hepatitis C infection is very rarely treated among hemodialysis patients","volume":"38","author":"Goodkin","year":"2013","journal-title":"Am J Nephrol"},{"key":"2025102312490093100_gfw023-B25","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-na\u00efve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER Study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"2025102312490093100_gfw023-B26","article-title":"Safety, and anti-viral efficacy and pharmacokinetics (PK) of sofosbuvir (SOF) in patients with severe renal impairment","volume":"60","author":"Gane","year":"2014","journal-title":"Hepatology"},{"key":"2025102312490093100_gfw023-B27","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)30162-8","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: real-world experience from HCV-target","volume":"62","author":"Saxena","year":"2015","journal-title":"J Hepatol"},{"key":"2025102312490093100_gfw023-B28","author":"Desnoyer"},{"key":"2025102312490093100_gfw023-B29","article-title":"Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C infection after kidney transplantation","author":"Kamar","year":"2015","journal-title":"Am J Transplant 20 Nov"},{"key":"2025102312490093100_gfw023-B30","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.13620","article-title":"Successful treatment on hepatitis C in renal transplant recipients with direct-acting antiviral agents","author":"Sawinski","year":"2016","journal-title":"Am J Transplant 5 Feb"},{"key":"2025102312490093100_gfw023-B31","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/S0140-6736(15)00381-5","article-title":"Towards eradication of the hepatitis C virus from dialysis units?","volume":"386","author":"Jadoul","year":"2015","journal-title":"Lancet"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/32\/1\/32\/9675101\/gfw023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/32\/1\/32\/9675101\/gfw023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:49:41Z","timestamp":1761238181000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/32\/1\/32\/2931150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,22]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,3,22]]},"published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfw023","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,1]]},"published":{"date-parts":[[2016,3,22]]}}}